<DOC>
	<DOCNO>NCT01298336</DOCNO>
	<brief_summary>The purpose study determine 6-months sputum conversion rate clarithromycin moxifloxacin contain regimen patient M. xenopi pulmonary infection .</brief_summary>
	<brief_title>Treatment Mycobacterium Xenopi Pulmonary Infection</brief_title>
	<detailed_description>In France , Mycobacterium xenopi second non-tuberculous mycobacteria responsible pulmonary infection . There data literature regard treatment apart two small randomize trial ( 42 34 patient , respectively ) French retrospective study ( 136 patient ) . So , decide conduct prospective randomize multicenter study evaluate two treatment regimen Mycobacterium xenopi pulmonary infection 6-months sputum conversion . Main objective : To determine 6-months sputum conversion rate clarithromycin moxifloxacin contain regimen patient M.xenopi pulmonary infection accord ATS / IDSA 2007 criterion . Secondary Objectives : To compare rate sputum conversion 3 6 month treatment clinical radiological outcome 12 month mortality . primary endpoint : Result culture respiratory sample 6 month start treatment.Culture sample take 6 month start treatment M. xenopi either positive ( presence M. xenopi colony without smear positive ) negative smear culture negative ( see data collection measurement method ) . Study plan : Any patient least one positive pulmonary M. xenopi sample may eligible . If patient underwent ATS / IDSA 2007 criterion M. xenopi pulmonary infection ( clinical , radiological microbiological evaluation ) , absence exclusion criterion , patient randomize one two treatment arm ( rifampicin+ ethambutol + clarithromycin rifampicin + ethambutol + moxifloxacin ) . A clinical , radiological , microbiological pharmacological monitoring do randomized patient . The recommended treatment duration 12 month conversion maximum duration 18 month . Number patient require : This prospective randomized study 2 parallel group . The primary endpoint consider whole study population . For Î± risk 5 % , accuracy 10 % , expect conversion rate 70 % total 80 patient require . For 15 % rate non evaluable patient ( die , lose follow-up ) need include 92 patient . Study Duration : Inclusion 24 month minimum follow-up 6 month ( meet main objective ) , possible follow-up 12 month per patient meet overall objective study . Prospects : To establish new treatment recommendation M.xenopi pulmonary infection , base microbiological clinical efficacy criterion tolerance criterion .</detailed_description>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Mycobacterium Infections , Nontuberculous</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>The patient and/or legal representative patient provide write informed consent inclusion study The patient age 18 old The patient sign functional respiratory ( cough , sputum , hemoptysis , dyspnea , chest pain / general sign ( asthenia / anorexia / weight loss ) The patient creatinine clearance 30 ml / min The patient underwent thoracic scan old one month first positive bacteriological sample . The patient underwent bronchoscopy sample conduct territory correspond radiographic The plausible alternative diagnostics eliminate use thoracic scan bronchoscopy The patient least two positive culture M. xenopi sputum collect two separate day AND/OR positive culture M. xenopi bronchoalveolar lavage bronchial aspiration direct AND / OR transbronchial biopsy lung biopsy surgical histology mycobacterial infection ( granuloma Ziehl positive ) culture positive M. xenopi , AND / OR biopsy histology compatible mycobacteriosis one positive sputum culture M . xenopi The patient willing able take study treatment throughout duration If woman childbearing age , patient ready use duration test contraception method estrogenprogestin The patient participate another study evaluate investigational drug within 30 day prior enrollment study agree participate another study duration study The patient inform doctor agree data process study The patient understand / read French difficulty understand objective study The patient health insurance coverage Hypersensitivity molecule ( rifampicin , ethambutol , moxifloxacin , clarithromycin ) Any patient relapse lung infection M. xenopi The patient treat molecule interfere cytochrome P450 replace another therapeutic class The patient treat prolong QT molecule replace another therapeutic class The patient treat alkaloid ergot , cisapride , biperidil , pimozide , mizolastine The patient heart failure leave ventricular ejection fraction 30 % Discovered balance sheet history , find patient infection human immunodeficiency virus HIV 1 2 long QT ECG / arrhythmias clinically significant bradycardia judge investigator cytolysis transaminases increase 5 time normal renal failure creatinine clearance 30 ml / min The patient cirrhosis Child Pugh C / porphyria There pregnancy breastfeed The patient inability meet protocol requirement , include active substance abuse , accord investigator . The patient history tendinopathy fluoroquinolone The patient congenital galactosemia , malabsorption glucose galactose , lactase deficiency The patient NORB ( abnormality visual field color vision test eye examination prior ) Any situation , opinion investigator , would imply participation study interest patient There risk difficulty monitoring , imminent transfer different region country</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Mycobacterium Xenopi Pulmonary Infection</keyword>
	<keyword>Clarithromycin</keyword>
	<keyword>Moxifloxacin</keyword>
</DOC>